Navigation Links
Chiasma to Present at the UBS Global Life Sciences Conference
Date:9/14/2011

NEW YORK and JERUSALEM, Sept. 14, 2011 /PRNewswire/ -- Chiasma, Inc., a privately held biopharma company, announced that Fredric Price, Chiasma's Chairman & CEO, will present an overview of the Company at the UBS Global Life Sciences Conference at the Grand Hyatt, New York, New York, on Monday, September 19, 2011 at 1:30 PM.

Chiasma's investigational new drug Octreolin™ is an oral form of octreotide acetate being developed first for the oral treatment of acromegaly, a hormonal disorder that results from an excess of growth hormone.  The Company successfully completed 4 clinical studies with Octreolin in healthy volunteers, having established a pharmacokinetics profile similar to that of subcutaneously injected octreotide acetate.  In addition, Octreolin demonstrated the ability to reduce growth hormone.  No serious adverse safety events were reported in any of the studies.  A trial in patients will commence in October 2011.  Chiasma intends to file an NDA using the 505(b)(2) regulatory pathway in the US and its EMA equivalent, the Hybrid Application in Europe.

Octreolin is also being developed as a chronic treatment for patients with Portal Hypertension (PHT); a Phase 2 proof of concept trial for this new orphan indication (no drugs are approved for PHT in the US) was initiated in September 2011.  The Company has a pipeline of products that are currently in preclinical development including one in renal disease that will enter the clinic in mid-2012.

About Chiasma

Chiasma develops new drug products based on its proprietary Transient Permeability Enhancer (TPE) technology, which enables oral delivery of macromolecules (up-to 20 kDa) and poorly-absorbed small molecules into the portal system and then to the systemic circulation.  The TPE technology not only enables their being converted from injectable to oral, but importantly can result in the development of new indications.

Ch
'/>"/>

SOURCE Chiasma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Chiasmas Octreolin™ (Oral Octreotide) Shown to Inhibit Growth Hormone in Healthy Subjects
2. Chiasma Grants Option to License Transient Permeability Enhancer (TPE) Technology for Small Molecule Products
3. Savient Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
4. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
5. Heska to Present at LD MICRO Invitational on September 22, 2011
6. Isis Pharmaceuticals to Present at the UBS Global Life Sciences Conference
7. BioMarin to Present at the UBS Global Life Sciences Conference
8. Henry Schein to Present at the CL King 9th Annual Best Ideas Conference 2011
9. PDL BioPharma to Present at Upcoming Investor Conferences
10. Pacira Pharmaceuticals, Inc. to Present at UBS Global Life Sciences Conference
11. Positive Results From Avanafil Phase 3 Study in Diabetics Presented at the 47th EASD Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... , Oct. 24, 2014  As the building ... a company access to diverse skill sets and ... round-the clock business hours for efficiency. However, effectively ... According to recent research, more ... as seeing a project not move forward due ...
(Date:10/22/2014)... Oct. 22, 2014  Cephasonics, a technology-innovation leader with ... the cQUB™-1 (cQuest Ultrasound Box™-1), the first product in ... and manufactured by Cephasonics for purchase by companies to ... Cephasonics will be showcasing the cQUB-1 for the first ... in Chongqing, China from October ...
(Date:10/22/2014)...  Quest Diagnostics (NYSE: DGX ), the ... that its Board of Directors has elected Jeffrey M. ... 1, 2014. Including Dr. Leiden, the Board has 11 ... and CEO of Vertex Pharmaceuticals.   Dr. Leiden has ... in the pharmaceutical and biotechnology industries as well as ...
Breaking Medicine Technology:Work Around the Clock: Successfully Building & Managing Global Virtual Teams 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 3Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 2Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 3
... June 17 Medical Simulation Corporation (MSC) proudly announces ... New York ,s largest health system and recipient of the ... The agreement includes the sale of MSC,s endovascular simulation system, ... services to advance North Shore,s education and patient safety goals ...
... ePharmaSolutions, a leading provider of clinical research technologies and ... Visit Report) application with new features to support online and offline ... with leading CTMS systems. , ... "Our latest release provides study monitors with the option ...
Cached Medicine Technology:Medical Simulation Corporation Signs Agreement With North Shore-LIJ Health System 2Medical Simulation Corporation Signs Agreement With North Shore-LIJ Health System 3ePharmaSolutions Launches New Version of Electronic Monitor Visit Report Application With Industry-Leading Online and Offline Capabilities 2
(Date:10/25/2014)... Market Research Report on ... is a professional and in-depth market survey ... The report firstly reviews the basic information ... and manufacturing technology. The report then explores ... Diagnostics listing their product specification, capacity, Production ...
(Date:10/25/2014)... NC (PRWEB) October 25, 2014 Mesothelioma ... who continued to receive pemetrexed (Alimta), after his combination ... read the full story , just posted on the ... from Uji Tokushukai Medical Center in Japan suggests that ... mesothelioma patients who cannot tolerate higher doses ...
(Date:10/25/2014)... getting the right amount of sleep might raise your ... Those who sleep less or more than the recommended ... prone to developing the chronic condition, which causes inflammation ... that duration and quality of sleep are key factors ... "Both short and long durations of sleep have ...
(Date:10/25/2014)... Randy Dotinga HealthDay Reporter ... tests are developed that spot increased risks for certain cancers, ... about getting screened. But a new study suggests that, ... People who found out their genes doubled their risk of ... risk to get screened. "It didn,t make any difference, ...
(Date:10/22/2014)... On October 22, CBS will air an episode ... fictional and real. The Charles E Holman Morgellons ... advocacy and philanthropy in the battle against Morgellons Disease, ... impart truth and clarity about this misunderstood and routinely ... about Morgellons Disease (MD) and most people ...
Breaking Medicine News(10 mins):Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 3Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 4Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2Health News:Knowing Genetic Risk for Cancer May Not Change Behavior 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3
... an incidence rate between 0 and 2.6% (average 0.3%) in ... generally well tolerated by patients, causing a delay in medical ... pediatrician faced with diagnosis and treatment of tinea of the ... tinea of the nails was observed in the Hospital del ...
... wellbeing in rich countries might depend more on reductions in ... study published today on bmj.com . , Poorer ... But a recent UNICEF report detailing 40 indicators of ... fared worse than in any of the other rich countries. ...
... Treatment ... Worldwide, LOS ANGELES, Nov. ... develop an AIDS vaccine have,announced that their efforts have stumbled or, in ... was halted last week,when its vaccine was suspected of actually making some ...
... Patients Ages 10 to 17 ... ... ,Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company (NYSE:,BMY) announced today that ... a Priority Review to the supplemental New,Drug Application (sNDA) of the atypical ...
... care fraud,becoming more organized, sophisticated, and prevalent, ... Investigative Units,(SIUs), state and federal agencies, and ... Health Care Anti-Fraud Association (NHCAA),s Annual,Training Conference, ... learn,more about new fraud schemes and explore ...
... against prescribing drug to patients who are already depressed ... take the weight-loss drug rimonabant may face heightened risks ... The finding follows a recommendation by a U.S. Food ... not approve the diet drug because of continuing concerns ...
Cached Medicine News:Health News:Tinea of the nails underdiagnosed in children 2Health News:Low standards of child well-being linked to greater income inequality 2Health News:AIDS Vaccine Failures Highlight Need to Focus on Lifesaving Treatment, Says AHF 2Health News:ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration 2Health News:ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration 3Health News:ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration 4Health News:ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration 5Health News:ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration 6Health News:NHCAA Annual Training Conference Bringing Together Law Enforcement, Health Insurers to Fight Health Care Fraud 2Health News:NHCAA Annual Training Conference Bringing Together Law Enforcement, Health Insurers to Fight Health Care Fraud 3Health News:Diet Drug Rimonabant Tied to Depression, Anxiety 2Health News:Diet Drug Rimonabant Tied to Depression, Anxiety 3
... Upper extremity fixator has been designed to ... by allowing independent movement of its clamp ... goals has been to reduce complexity of ... ease of use. The Hoffmann® II Compact™ ...
The Medium External Fixator has a medium Combination Clamp that connects rod to rod or pin to rod as well as a Medium Multi-Pin Clamp that connects pins to rods allowing parallel pin placement....
The DFS MiniFixator is a lightweight, external device for the treatment of small bone fractures and osteotomies....
... components for individual indications. XCaliber covers a ... an innovative composite plastic material, XCaliber is ... This means it's easier to handle, easier ... patient. ,Comes pre-assembled, packaged sterile, and ready ...
Medicine Products: